Biopharma laboratory research environment — Katogen operator-led consulting

Intelligence · Strategy · Operations

IntelligenceSee it first.StrategyDecide right.OperationsGet it done.Intelligence — See it first. Strategy — Decide right. Operations — Get it done.

Most consultants have never run a company. Our Founder, Doug Drysdale, has — 17 acquisitions, $4B+ raised, and CEO of Alvogen and Cybin. Katogen pairs that operator judgment with proprietary intelligence tools and embedded execution teams. Not a junior team running a framework. An operating partner who has solved your problem before.

Strategic vision in biopharma — Katogen operator-led firm

Photo by Ion Fet on Unsplash

How we work

One operating model. Three reinforcing pillars.

Biopharma advice is cheap. Execution is rare. Katogen is built across three pillars so the same operators who help you see the move and decide it are the ones who help you make it.

The Katogen Engine

Each pillar makes the next one sharper.

Intelligence surfaces the signal. Strategy turns it into the right decision. Operations executes — and what we learn in execution feeds straight back into the intelligence layer. It's a loop most firms can't offer, because they only do one part of it. We built all three under one roof, run by the same operators.

What typical biopharma consultants don't have.

  • No operator experience.

    They studied the industry. We've run it — 17 acquisitions, $4B+ raised, four companies built or turned around.

  • No intelligence tools.

    They send a deck. We give you proprietary, operator-augmented AI that works between the meetings.

  • No operational functions.

    They recommend and leave. We embed a team that executes to your milestones.

Most firms give you a recommendation. Katogen gives you the intelligence to see it, the judgment to decide it, and the team to execute it.

Operator judgment

The Katogen Difference

There is a difference between advising on a deal and closing one. Katogen is built on 35 years of building, not just advising. Every recommendation we make is grounded in real decisions, real companies, and real consequences. We have navigated product launches, capital raises, M&A integrations, and board-level crises. We know what works and what fails - because we have lived both.

Strategy

Fractional Executive, Board & Advisory

Operator-led leadership for inflection points — M&A, capital raises, turnarounds, and board build-out — without a full-time hire. One pillar capability inside Strategy; explore the full practice on the dedicated page.

Fractional & board advisory

Biotechnology research laboratory — Katogen biopharma

Photo by D koi on Unsplash

Context

The Biopharma Landscape

The biopharma sector is under pressure right now. Patent cliffs are accelerating. M&A activity is increasing. Capital markets are tighter than they have been in a decade. Competition is intensifying across every major therapeutic area. Companies that move fast with the right intelligence, the right decision, and a team to execute will capture the value. The rest won't. Katogen exists for the companies that want to move fast and get it right.

Ready To Move From Vision To Value?

If you are navigating a deal, a capital raise, or a growth challenge - let's talk. Engagements are structured as project-based consulting, retained advisory, or fractional executive arrangements. Every engagement starts with a direct conversation with our Founder. No sales team. No junior handoff. Just an operator who has done this before.